Study Comparing BMS-790052 (Daclatasvir) to Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Untreated Hepatitis C Patients

Allocation: Randomized Stratified

Inclusion Criteria:

- Subjects chronically infected with HCV genotype 1a or 1b

- HCV RNA viral load ≥ 10,000 IU/mL

- No prior treatment including but not limited to interferon, ribavirin and
direct-acting antivirals

- if no prior history of cirrhosis liver biopsy within 3 years or Fibroscan® within 1
year

- Body Mass Index (BMI) of 18 to 35 kg/m2

- Negative for Human immunodeficiency virus (HIV) and Hepatitis B

Exclusion Criteria:

- Evidence of decompensated liver disease

- Evidence of medical condition contributing to chronic liver disease other than HCV